Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.53−0.03 (-1.92%)
Close on Nov 17, 2026Market cap $297.61MP/E –Yield –
Altimmune operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Altimmune's operating income for the twelve months ending Jun 30, 2026 was -$100.23M. For fiscal 2025 it was -$94.49M. The highest annual figure on record is -$3.40M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$94.49M | – |
| FY2024 | Dec 31, 2024 | -$103.17M | – |
| FY2023 | Dec 31, 2023 | -$95.93M | – |
| FY2022 | Dec 31, 2022 | -$87.74M | – |
| FY2021 | Dec 31, 2021 | -$96.91M | – |
| FY2020 | Dec 31, 2020 | -$54.80M | – |
| FY2019 | Dec 31, 2019 | -$21.46M | – |
| FY2018 | Dec 31, 2018 | -$42.83M | – |
| FY2017 | Dec 31, 2017 | -$52.05M | – |
| FY2016 | Dec 31, 2016 | -$11.09M | – |
| FY2015 | Dec 31, 2015 | -$3.40M | – |
| FY2014 | Dec 31, 2014 | -$10.19M | – |
| FY2013 | Dec 31, 2013 | -$10.84M | – |
| FY2012 | Dec 31, 2012 | -$6.27M | – |
| FY2011 | Dec 31, 2011 | -$11.73M | – |
| FY2010 | Dec 31, 2010 | -$23.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.23M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.92M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.86M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.55M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.33M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.35M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.06M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.44M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.99M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.56M | – |
| Q3 FY2017 | Sep 30, 2017 | -$30.95M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.01M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.52M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.51M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.79M | – |
See a number that looks wrong?